Recently, we reported that the level of G2M cell cycle pathway activity may serve as a useful tool for identifying patients who are likely to metastasize and have a poor survival in estrogen receptor (ER)-positive breast cancer using GSVA [21]. The gene discussed is ESR1; the disease is breast cancer.